Radiation therapy in patients with head and neck cancer has a toxic effect on mucosa, the soft tissue in and around the mouth. Hence mucositis is a serious common side effect and is a condition characterized by pain and inflammation of the surface of the mucosa.
Introduction
Radiation therapy in patients with head and neck cancer has a toxic effect on mucosa, the soft tissue in and around the mouth. Hence mucositis is a common side effect and is a condition characterized by pain and inflammation of the surface of the mucosa. Mucositis causes serious oral pain which makes the food intake of the cancer patients painful. It is known that mucositis is in general developed 14 days after starting radiotherapy. Although the mucosa recovers during breaks of and following the radiotherapy course the recovery will depend on the type of tissue involved and on its location. Hence there is a need to quantify the damage to the mucosa by different mouth sites. Here the clinical objective is in assessing the sensitivity to radiation of different mouth sites in order to improve planning of radiation therapy to avoid these side effects.
To obtain clinical evidence observational data were collected on a total of 75 patients receiving radiation therapy between September 2006 and February 2012. During the course of radiation therapy mucositis was assessed in 8 mouth sites approximately twice a week. For assessment an ordinal severity score with 5 levels was used, ranging from 0 (no change in tissue) to 4 (necrosis). At each assessment cumulative dose and the median value of the percentage site specific dose was recorded, so that the site specific cumulative dose could be derived. In addition all relevant patient characteristics were recorded.
Statistical analyses on oral mucositis as an adverse effect of therapy are often simplistic. For example Sakellari et al. [13] analyse oral mucositis in patients after high-dose chemotherapy using logistic regression of cumulative incidence of mucositis. The approach neglects the time course of the disease (oral mucositis), the fact the end-point is ordinal and the dosage of the chemotherapy.
Our aim is to answer the clinical question by modelling the outcome variable mucositis score as a function of patient specific variables and (site) specific cumulative dose. Then the sensitivity of different mouth sites to radiation therapy can be assessed by estimating the effect of mouth sites on the mucositis score, after adjusting for confounder variables, the most obvious being site specific cumulative dose. Due to the observational nature of the data we need to adjust for confounder variables.
These longitudinal data on the course of mucositis and cumulative dose of radiation therapy have a complex structure and pose a number of statistical challenges:
(1) the outcome is ordinal; (2) We have a multivariate outcome variable, as we have mucositis scores assessed for eight different sites per patient and time points (evaluation); (3) the outcome is longitudinal and we expect that repeated observations of individuals are correlated; (4) due to the fact that the mucosa can recover during radiation breaks a non-linear effect of sites specific cumulative dose on the mucositis score is plausible. (5) Finally, it is also likely that the effect of site specific dose differs by site, i.e. there is an interaction between site and site specific dose. We address these challenges with a flexible multivariate random effects proportional odds model. This is an extension of the proportional odds model [11] which is used for ordinal response variables and belongs to the class of generalized linear models used for modelling the dependence of an ordinal response on discrete or continuous covariates. The model is an extension of the multivariate random effects models for longitudinal data described in Verbeke et al. [15] . See also Faraway [7] and Agresti [1] for some recent expositions of ordinal response models.
The data
Observational data were collected on a total of 75 patients receiving radiation therapy for head and neck cancer between September 2006 and February 2012 in the Radiation Oncology Department, Medical Center, University of Freiburg. Three-dimensional radiation planning techniques and standard fractionation (5 x 2.0 Gy/wk) were followed. The total dose to the tumour was 60 Gy to 70 Gy. Radiation breaks were not allowed. Additional cisplatin 100 mg/m2 was given intravenously on days 1 and 22 (and on day 43 for patients undergoing primary definitive radiation or with residual cancer following surgery). The oral mucosa was evaluated in eight mouth sites (upper lip, lower lip, floor of mouth, right cheek, left cheek, tongue, soft palate hard palate) by using the five level NIH-CTC oral toxicity scale ((0) no mucositis, (1) erythema, (2) ulcer, (3) confluent ulcer, (4) necrosis). Twice-weekly assessments (at least 3 days apart) continued throughout radiotherapy and then until resolution of oral mucositis. At each assessment the cumulative dose to the tumor and the median value of the percentage of the site specific dose was recorded, so that the site specific cumulative dose could be derived. In addition all relevant patient characteristics were recorded. All study procedures were reviewed by the local ethics committee and all patients provided written consent.
The mucositis progressions on eight different sites of four randomly sampled patients are depicted in Figure 1 , showing the ordinal scale of mucositis scores as well as longitudinal multivariate structure.
Our main goal is to investigate the relationship between mucositis progression and potential risk factors. Let y i jl be the mucositis score for individual i = 1, . . . , 75, evaluation j = 1, . . . , (sex i and age i ), site l (hard palate, soft palate, tongue, mouth floor, upper lip, lower lip, left cheek, right cheek), cumulative (radiation) dose (cumdose i j ), median percentage dose of the site (perc il ), the site specific cumulative dose cumdos.site i jl and the site specific volume il .
The site specific dose cumdos.site i jl at evaluation j is determined by multiplying the total cumulative dose cumdose i j with the median percentage dose of the site (perc il ). The median percentage dose per site (perc il ) is assumed to be constant over time as it is the median percentage of cumdose i j at the site receiving radiation over the entire radiation schedule. Apart for some exceptions, time in days is proportional to cumulative dose (Figure 3 ), hence in the following modelling we will use cumulative dose and site specific cumulative dose. Table 1 shows that no mucositis (0) is observed most often, followed by erythema, ulcer, confluent ulcer and necrosis. Figure 2 shows frequencies of mucositis score by site and shows that on the lower and upper lip high mucositis scores are rarer than at other sites. Figure 2 shows the cumdos.site i jl by site and mucositis score: upper and lower lip tend to receive the lowest levels of site specific dose cumdos.site i jl and mouth floor, tongue and soft palate tend to receive the highest doses.
Biologically effective dose (BED)
Here we analyse physically cumulative dose. To eventually correct for repopulation we also calculated the biologically effective dose (BED) using the so called αβ model, see for a review
Fowler [8] . Here we assume α β = 10Gy, where α and β are the coefficients for dose and dose 2 in a linear model for cell kill. In the case of mucosa the α = 0.3Gy −1 , the onset of accelerated repopulation is 7 days and the average doubling time during accelerated repopulation is assumed to be 2.5. 
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As outlined in the introduction due to the complex data situation we require a model for an ordinal multivariate outcome variable. In addition the model should be able to accommodate the correlated repeated measures of individuals and should allow effects of continuous variables to be non-linear, and we also want to test whether there is an interaction between site and site specific dose.
The proportional odds model
The proportional odds model [11] addresses the first point, as it is a class of generalized linear models used for modelling the dependence of an ordinal response on discrete or continuous covariates. It can also be seen as an extension of a logistic regression model [4] , as we could model the mucositis scores collapsed into two categories for the two events Y ≤ r and Y > r as shown in Table 1 . But this leads to loss of efficiency, resulting in larger standard errors [1] .
Let Y i denote the mucositis severity score in the range 0, ..., 4 for individual i. Then we model the cumulative probability of Y i being less or equal to mucositis score r, P(Y i ≤ r) on the logit scale. That is on the log scale of the (cumulative) odds of the event Y i ≤ r:
On the logit scale the model is linear which makes it computationally convenient. In the above example the x i is a continuous variable, e.g. cumulative dose. In the case of mucositis a plausible way of constructing model 1 is to use the concept of an unobserved continuous response.
Suppose U i is the unobserved mucositis severity on a continuous scale with U i = x i β + i . Although we only observe the discrete mucositis scores, Y i = r is only observed if α r−1 < U i ≤ α r .
The "cut-points" α r are unknown points on the continuous mucositis severity scale. Lets also assume that i = U i − x i β has a logistic distribution function F(.) with F(.) = exp(.) 1+exp (.) then:
This model is mathematically equivalent to model 1. We also note the intuitive interpretation, if β > 0 as x i increases also the P(Y i > r) increases. For example, as cumulative dose increases, it is more likely that a high mucositis score is observed. In a model containing a linear effect for cumdos.site the odds ratio of the event Y ≤ r for x 1 = cumdos.site − 10 and x 2 = cumdos.site, whilst keeping all other variables fixed, is
When using the same β across all categories, we assume that the odds ratio does not depend on the category r, i.e. these cumulative odds are proportional across all categories. In a model containing a factor variable for site based on the frequencies in 
A flexible multivariate random effects proportional odds model
In order to address all of the model requirements we extend the proportional odds model by incorporating a multivariate response, random effects and non-linear functions of continuous variables. This is an extension of the class of generalised additive mixed models [6, 16] , because the logistic distribution we are assuming for the latent response variable U i and the error i does not belong the exponential family. Below we introduce these different features step by step.
The model for individual i, assessment time index j, and site l is specified as
and U i jl = η i jl + i jl and i jl follows the logistic distribution. 
the smooth function f is represented using a thin plate regression spline [16] with a penalty based on the second derivative of the smooth function and now
The model above can be further extended. Besides testing whether sites effects differ, we are also interested in testing whether the effect of site specific dose differs by site. For this we introduce an interaction between site and site specific dose, by letting f vary by site l : full model:
Parameter estimation
Inference can be based on Markov chain Monte Carlo (MCMC) [5, 2] , on a mixed model approach using restricted maximum likelihood (REML) [10, 6, 17] . All of these are implemented in the BayesX package [3, 14] . We present estimates using a Laplace approximation to REML of Wood et al. [17] , implemented in the gam() function of the R ( [12] ) package mgcv. In the supplementary material we supply example R code for model fitting in both BayesX and in
mgcv.
Although the above reduced model (3) and the full model (4) include additive non-linear predictors and random effects they can be expressed as a penalised generalised linear model (GLM); 
Model selection and validation
We consider the Akaike information criterion (AIC) and the Bayesian information criterion (BIC)for model selection. The AIC is defined as AIC = −2l(θ) + 2ed f , the BIC is BIC = −2l(θ) + log(n)ed f , where l is the conditional log likelihood given the penalised parameters, ed f are the effective degrees of freedom, here estimated by the trace of the matrix that maps the un-penalised estimates onto the penalised estimates corrected for the smoothing parameter uncertainty as described in Wood et al. [17] ; see also Greven and Kneib [9] . We also consider the root mean square prediction error (RMSPE) estimated by cross-validation as a selection criterion. For the cross-validation we leave out in turn each of 15 mutually exclusive sets of patients and fit the model to the remaining patients data and predict the probabilities for the outcomes, the mucositis scores. Having obtained predictions for each set of patients left out we can estimate the root mean prediction error for each mucositis score.
In the modelling we combine the mucositis scores 3 (confluent ulcer) and 4 (necrosis) due to the low frequencies of score 4. We start the model selection by reducing the complexity of the full model (4). Table 5 gives an overview of the considered models and the results of selection criteria are shown in Table 5 . The most complex model is the full model (4) overall has marginally the best goodness of fit, but with regards to parsimony the reduced model (3) with the terms for age and sex removed comes out best. Hence the final selected model is best model:
where β 2 is the parameter vector for the 8 sites. Checking the residuals of the best model (5), shows that the model fits well. The distributional assumptions of the model are correct, i.e.
the residuals follow a logistic distribution ( Figure 5 ) and the random effects follow a normal distribution ( Figure 6 ). The assumption of proportional odds is adequate and has been checked using diagnostic plots (not shown).
The model selection results also show that cumdos.site is by far the most important predictor, followed by site. Results also show that effect of site specific cumulative dose is not linear, as the goodness of fit is substantially reduced when the we use a linear effect for cumdos.site. This is also apparent from the estimated smooth function of cumdos.site shown in Figure 6 . The cumulative dose has initially, up to approximately 20 Gy quite a strong effect on mucositis, and this effect becomes weaker for > 20 Gy. There is a considerable amount of uncertainty about the effect for high cumulative dosages. Figure 7 shows the cumulative odds of having a score greater than r over having a score less or equal to r, with hard palate as the reference. e.g.:
This shows that, after adjustment for cumulative radiation dose, upper, lower lip and mouth floor are much less likely to have a higher mucositis score than the other sites. The site soft palate is most likely to have a high score. 
Discussion
In this observational study the radiotherapists made an effort to prevent much damage of mucositis and randomized assignment of radiation dose for each site was not feasible. The assigned dose has been carefully planned to avoid severe mucositis especially for what the practitioners thought are the most vulnerable sites, upper and lower lip. However, the assigned dose has been carefully planned to avoid severe mucositis especially for the most vulnerable sites, that is the sensitivity of sites and site specific cumulative dose are confounded. For estimating the sensitivity of sites we need to adjust for cumulative dose in a statistical model. The selected best model (5) contains site specific cumulative dose as a non-linear effect, and the results show that after adjusting for site specific cumulative dose we find that sensitivity to radiation varies by site. The upper and lower lip are, after adjusting for cumulative dose, the least vulnerable to radiation, followed by mouth floor (Figure 7 ). More vulnerable than the latter are the sites tongue, right and left cheek and most vulnerable to radiation are soft and hard palate. We note that the ranking of sensitivity of sites is not in the same order than if we just consider marginal frequencies of mucositis scores (Figure 2 ), due to the confounding of cumulative dose with sites. On the boxplots of cumulative dose by site in Figure 7 we have marked the cumulative dose when mucositis score 3 or 4 first occurred. This shows that for upper and lower lip mucositis occurs rarely and at doses higher than those where it occurs at other sites. We can also see that there is a good overlap in cumulative dose when mucositis first occurred between sites. Table 1 . Note that we do not use r = 3, because in the analysis we combined mucositis scores 3 and 4.
Our results depend on the accurate measurement of percentage median dose arriving at individual sites throughout the radiation schedule. It is also worth noting that we have not adjusted for the absolute volume of the sites in our model, but we assume that the volume does not differ substantially between sites. It is future work to investigate whether site volume has an effect on mucositis. In our analysis we have used cumulative dose rather than biological effective dose, as the cumulative dose achieved the best model fit.
As in any statistical investigation, inference relies on the validity of the model. We have taken great care to avoid model misspecification by using a flexible multivariate random effects proportional odds model to estimate the effects. The model is complex, but this level of complexity is required in order to reflect the data generating mechanism. We have carried out a thorough model selection based on the AIC, BIC and the root mean square prediction error estimated by 15-fold cross-validation. The model deals with the repeated multivariate ordered categorical outcome measures of individuals via random intercepts for individuals. The model also has
shown that the effect of cumulative dose is not linear, and that there is a possible interaction between site and site specific dose, as we could not entirely reject the full model (4).
